Delivery Order SPE2DB20D2014-SPE2DB24FB81Z
- Not listed
- This federal contract award is for the delivery of Rocuronium 50 mg/5 ml vials to the Defense Logistics Agency (DLA). The $2,179.80 firm-fixed-price delivery order was awarded to the prime contractor, Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract has a period of performance through March 13, 2024 and was not designated with a set-aside. Amerisourcebergen Drug Corp holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
- This federal contract award was made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, to provide 4,558,029,625 units of the drug Rocuronium 50 mg/5 ml vial with a 5 ml volume. The $1,097.76 firm fixed price delivery order has an ultimate completion date of August 9, 2022. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical through November 2026, which serves as a primary vehicle...
- This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, is for the delivery of 4566787552 vials of ROCURONIUM 50 MG/5 ML, a pharmaceutical product. The $1,421.76 fixed-price delivery order was awarded by the Defense Logistics Agency (DLA) Troop Support Medical, a component of the Department of Defense responsible for medical supply chain management. The contract has an ultimate completion date of December 24, 2024. Amerisourcebergen holds a larger...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, as the prime contractor. The contract, a firm fixed price delivery order worth $2,035.24, is for the supply of 4564158471 ROCURONIUM 50 MG/5 ML VIAL 5ML to support military treatment programs and facilities. The contract has an ultimate completion date of April 4, 2024 and does not have a set-aside designation. Amerisourcebergen Drug Corp...
- This federal contract award is for the supply of 4567389512 - ROCURONIUM 100 MG/10 ML VIAL 10ML, a pharmaceutical product, to the Defense Logistics Agency (DLA), a defense agency. The contract was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, on February 26, 2025, with a ceiling value of $2,837.58 and a completion date of February 27, 2025. The contract is a Firm Fixed Price Delivery Order, with no set-aside designation. AmerisourceBergen Drug Corp holds a...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,174.40 firm fixed-price delivery order is for the supply of 4566581070 ROCURONIUM 100 MG/10 ML VIAL 10ML, with a completion date of December 3, 2024. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for...
- The U.S. Defense Logistics Agency (DLA) Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Rocuronium 100 mg/10 ml vials on September 3, 2025. This non-set-aside, competitively awarded contract carries a ceiling value of $1,166.98 under a firm fixed-price arrangement, with an ultimate completion date of September 4, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the work...
- This federal contract award to Amerisourcebergen Drug Corp (Amerisourcebergen), a major pharmaceutical distributor, involves the delivery of 4565332483 - ROCURONIUM 50 MG/5 ML VIAL 5ML to the Defense Logistics Agency (DLA). The firm-fixed-price Delivery Order, valued at $1,846.80, has an ultimate completion date of August 5, 2024. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for...
- This is a federal contract award from the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,038.30 firm fixed-price delivery order is for the supply of ROCURONIUM 50 MG/5 ML VIAL 5ML, a medical product. The contract has an ultimate completion date of March 31, 2025. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
- This federal contract award to AmerisourceBergen Drug Corp provides for the delivery of 4566703854 - ROCURONIUM 50 MG/5 ML VIAL 5ML, a critical medical commodity used in healthcare settings. The firm-fixed-price contract, valued at $1,176.78, was awarded by the Defense Logistics Agency (DLA) Troop Support Medical, a division of the Department of Defense that procures medical supplies and equipment for military treatment facilities and other federal healthcare programs. The contract has an...
- SPE2DB20D2014Indefinite Delivery Contract
- SPE2DB20D2014-SPE2DB24FB81ZDelivery Order
This federal contract award is for the delivery of 100 mg/10 mL vials of the pharmaceutical product rocuronium. The contract was awarded by the Defense Logistics Agency (DLA), an agency of the U.S. Department of Defense, to the prime contractor Amerisourcebergen Drug Corp, a subsidiary of the major pharmaceutical distributor Amerisourcebergen Corporation. The contract has a total ceiling value of $1,819.11 and is a firm fixed-price delivery order with a completion date of May 7, 2024. It does not have a set-aside designation. Amerisourcebergen Drug Corp holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00 through December 31, 2025. This single-award IDC serves as the primary vehicle for Amerisourcebergen to deliver a comprehensive range of pharmaceutical products and medical supplies to DLA facilities supporting the Department of Defense worldwide. The company also holds a smaller IDC with the Department of Justice Federal Bureau of Investigation for similar medical products and prescription drugs, valued up to $750,000 through May 2024.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.8k | 5/6/24 |